Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary CD34+ Cells for Coronary Endothelial Dysfunction
NCT03471611Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2018
- Primary completion
- Oct 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous CD34+ cells in Coronary endothelial dysfunction (CED) and Coronary atherosclerosis (CAD), sponsored by Mayo Clinic. Primary endpoints: Number of subjects experiencing adverse events at 12 months, Number of subjects experiencing serious adverse events at 12 months and 1 more. Started Jun 2018; status: completed.
02
Drugs
autologous CD34+ cells
03
Conditions
Coronary endothelial dysfunction (CED)Coronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT03471611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471611.